<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0001513'>Obesity</z:hpo>, type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, and <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disease</z:e> correlate with infiltration to adipose tissue of different immune cells, with uncertain influences on metabolism </plain></SENT>
<SENT sid="1" pm="."><plain>Rats were fed a diet high in carbohydrates and saturated fats to develop diet-induced <z:hpo ids='HP_0001513'>obesity</z:hpo> over 16 weeks </plain></SENT>
<SENT sid="2" pm="."><plain>This nutritional overload caused overexpression and secretion of phospholipase A(2) group IIA (pla2g2a) from immune cells in adipose tissue rather than adipocytes, whereas expression of adipose-specific phospholipase A(2) (pla2g16) was unchanged </plain></SENT>
<SENT sid="3" pm="."><plain>These immune cells produce <z:chebi fb="11" ids="26333">prostaglandin</z:chebi> E(2) (<z:chebi fb="0" ids="26338">PGE</z:chebi>(2)), which influences adipocyte signaling </plain></SENT>
<SENT sid="4" pm="."><plain>We found that a selective inhibitor of human pla2g2a (5-(4-benzyloxyphenyl)-(4S)-(<z:chebi fb="1" ids="30396">phenyl</z:chebi>-heptanoylamino)-<z:chebi fb="0" ids="17418">pentanoic acid</z:chebi> [KH064]) attenuated secretion of <z:chebi fb="0" ids="26338">PGE</z:chebi>(2) from human immune cells stimulated with the fatty acid, <z:chebi fb="0" ids="15756">palmitic acid</z:chebi>, or with <z:chebi fb="0" ids="16412">lipopolysaccharide</z:chebi> </plain></SENT>
<SENT sid="5" pm="."><plain>Oral administration of KH064 (5 mg/kg/day) to rats fed the high-carbohydrate, high-fat diet prevented the overexpression of pla2g2a and the increased macrophage infiltration and elevated <z:chebi fb="0" ids="26338">PGE</z:chebi>(2) concentrations in adipose tissue </plain></SENT>
<SENT sid="6" pm="."><plain>The treatment also attenuated visceral <z:e sem="disease" ids="C0028754" disease_type="Disease or Syndrome" abbrv="">adiposity</z:e> and reversed most characteristics of <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e>, producing marked improvements in insulin sensitivity, <z:hpo ids='HP_0000833'>glucose intolerance</z:hpo>, and <z:hpo ids='HP_0001626'>cardiovascular abnormalities</z:hpo> </plain></SENT>
<SENT sid="7" pm="."><plain>We suggest that pla2g2a may have a causal relationship with <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:e sem="disease" ids="C0028754" disease_type="Disease or Syndrome" abbrv="">adiposity</z:e> and <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> and that its inhibition in vivo may be a valuable new approach to treat <z:hpo ids='HP_0001513'>obesity</z:hpo>, type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, and metabolic dysfunction in humans </plain></SENT>
</text></document>